Evaluation of the safety and effectiveness of intradermal administration of QR678 Neo ® hair growth factor formulation: A phase-IV, open-label, single

waynakyo

Experienced Member
Reaction score
434
i wouldn't get excited but worth a look?

Abstract​

Background: Intradermal administration of QR678 Neo® hair re-growth factor formulation has already proven its effectiveness and safety in treating androgenetic alopecia and female pattern hair loss.
Aim: This study aims to evaluate effectiveness and safety of hair re-growth factor formulation at multiple centers for reduction of hair fall and regrowth of hair in androgenetic alopecia and female pattern hair loss.
Materials and methods: An open-label, prospective, and interventional study was carried out at multiple centers of different countries. A total of 2428 patients with androgenetic alopecia and female pattern hair loss within the age range of 18-65 years were included in the study. Hair pull test, global photographic assessment, videomicroscopic assessment tests were performed at the beginning, after fourth and eighth sessions, and self-assessment through questionnaire related to satisfaction and side effects was carried out at beginning and at after eight session.
Results: Hair pull test was positive in only 12% of the patients after eight sessions. Beneficial results were noted in the global assessment score (mean-6) after fourth session and eighth session (mean-8). Huge improvement was noted in terminal hair count, vellus hair count, and hair density after eighth sessions. Also, with self-assessment score, a higher satisfaction score was noted. On long-term follow-up as well, no side effects were noted.
Conclusion: Intradermal administration of QR678 Neo® is an innovative, efficacious, and safe technique for the treatment of androgenetic alopecia and female pattern hair loss.
Keywords: QR678 Neo®; Hair re-growth; androgenetic alopecia.
 

TurboFixer

Established Member
My Regimen
Reaction score
176
so its injections of this stuff

S NoIngredientsQuantity
1Vascular endothelial growth factor0.01mg/L – 100mg/L

2Basic fibroblast growth factor0.01mg/L – 100 mg/L
3Insulin like growth factor0.01mg/L – 100mg/L
4Copper tripeptide 10.1mg/L – 500 mg/L
5Keratinocyte growth factor0.01mg/L – 100 mg/L
6Thymosin β40.005mg/L – 100 mg/L
7VitaminsVitamin A , Vitamin B1, Vitamin B2 , Vitamin B3 , Vitamin B5 ,Vitamin B6 , Vitamin B7 , Vitamin B12 , Vitamin C , Vitamin E , Vitamin I , Vitamin K
8MineralsCalcium, Sodium, Potassium, Magnesium
9Nucleic acids, Essential and non-essential amino acids


I don't think this looks very promising at all :(
 

John Difool

Senior Member
My Regimen
Reaction score
1,317
My june 2020 notes on this are posted below for reference with prices from a Chinese scamlab at the time. By now, this would have been known for getting results if it had.

Solution 3, comprising 0.0002 mg/0.1 ml of IGF-1, 0.0002 mg of bFGF, 0.0005 mg of VEGF and 0.0001 mg of KGF, 0.001 mg of copper tripeptide, and 1 × 10−6 mg of thymosin β4 in distilled water, gave the best response. Increase in concentration of the ingredients beyond that in solution 4 did not give any significant benefit in terms of number of mice growing hair or the diameter of hair growth region.



Final composition of the novel formulation (QR 678).
S. No. Ingredients Quantity
1 Vascular endothelial growth factor 0.01–100 mg/L
2 Basic fibroblast growth factor 0.01–100 mg/L
3 Insulin-like growth factor 0.01–100 mg/L
4 Copper tripeptide-1 0.1–500 mg/L
5 Keratinocyte growth factor 0.01–100 mg/L
6 Thymosin β4 0.005–100 mg/L
7 Vitamins Vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B7, vitamin B12, vitamin C, vitamin E, vitamin I, vitamin K
8 Minerals Calcium, sodium, potassium, magnesium
9 Nucleic acids, essential and nonessential amino acids

VGEF 0.01mg
FGF-2 0.01
IGF-1 0.01 50 mcg daily
GHK-Cu 100mg 0.5 milligrams/kilogram
KGF 0.01mg
Thymosin β4 0.005 7.66mg per week

Preparation of the formulation
Five milligrams of VEGF, 2 mg of basic FGF, 2 mg of IGF, 10 mg of copper tripeptide-1, 1 mg of KGF, and 0.01 mg of thymosin β4 additionally with pharmaceutically/cosmetically acceptable and appropriate dose of vitamins, minerals, amino acids, and nucleic acids are added to 1 ml of distilled water. The formulation is then biologically sterilized and bottled into vials of 5 ml each. The formulation of the present invention is stable and can be stored at room temperature (below 25°C).



1. VEGF (cas number: 127464-60-2) 0.1mg
2. FGF-2 (cas number: 106096-93-9) 3mg
3. IGF-1 LR3 (cas number: 946870-92-4) 3mg
4. KGF (cas number 148348-15-6) 3mg
5. GHK-Cu (cas number 49557-75-7) 15g
6. Thymosin Beta-4 (cas number 77591-33-4) 1g

1.VEGF CAS Number: 127464-60-2
USD100/0.1MG 98%
2.FGF-2 CAS Number: 106096-93-9
USD40/1MG 95%
3.IGF-1 LR3 CAS Number: 946870-92-4
USD22/1MG 95%
4.KGF CAS Number 148348-15-6
USD40/1MG
5. GHK-Cu cas number 49557-75-7
USD230/10G 98%
6. Thymosin Beta-4 cas number 77591-33-4
USD880/1G 98%
 
Top